| [1] Lee Y, Ahn C, Han JJ, Choi H, Kim J, Yim J, Lee J, Provost P, Rådmark O, Kim S, Kim VN. The nuclear RNase III Drosha initiates microRNA processing. Nature, 2003, 425(6956): 415-419.[2] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004, 116(2): 281-297.[3] Garzon R, Liu SJ, Fabbri M, Liu ZF, Heaphy CEA, Callegari E, Schwind S, Pang JX, Yu JH, Muthusamy N, Havelange V, Volinia S, Blum W, Rush LJ, Perrotti D, Andreeff M, Bloom-field CD, Byrd JC, Chan K, Wu LC, Croce CM, Marcucci G. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood, 2009, 113(25): 6411-6418.[4] Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 2005, 120(1): 15-20.[5] de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov, 2007, 6(6): 443-453.[6] Stevenson M. Therapeutic potential of RNA interference. N Engl J Med, 2004, 351(17): 1772-1777.[7] Kawasaki H, Taira K. Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature, 2004, 431(7005): 211-217.[8] Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science, 2004, 304(5670): 594-596.[9] Song G, Zeng HZ, Li J, Xiao LF, He YZ, Tang YH, Li YR. miR-199a regulates the tumor suppressor mitogen-activated protein kinase kinase kinase 11 in gastric cancer. Biol Pharm Bull, 2010, 33(11): 1822-1827.[10] Zhang ZY, Li ZJ, Gao CP, Chen P, Chen JJ, Liu WZ, Xiao SD, Lu H. miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest, 2008, 88(12): 1358-1366.[11] Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H, Okamoto K, Otsuji E. Circulating microRNAs in plasma of pa-tients with gastric cancers. Br J Cancer, 2010, 102(7): 1174-1179.[12] Sun QM, Gu HJ, Zeng Y, Xia Y, Wang Y, Jing Y, Yang L, Wang B. Hsa-mir-27a genetic variant contributes to gastric cancer suscep-tibility through affecting miR-27a and target gene expression. Cancer Sci, 2010, 101(10): 2241-2247.[13] Tsai KW, Hu LY, Wu CW, Li SC, Lai CH, Kao HW, Fang WL, Lin WC. Epigenetic regulation of miR-196b expression in gastric cancer. Genes Chromosomes Cancer, 2010, 49(11): 969-980.[14] Feng RH, Chen XH, Yu YY, Su LP, Yu BQ, Li JF, Cai Q, Yan M, Liu BY, Zhu ZG. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett, 2010, 298(1): 50-63.[15] Shinozaki A, Sakatani T, Ushiku T, Hino rR, Isogai M, Ishikawa S, Uozaki H, Takada K, Fukayama M. Downregulation of microRNA-200 in EBV-associated gastric carcinoma. Cancer Res, 2010, 70(11): 4719-4727.[16] Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, Uchida T, Hijiya N, Matsuura K, Fujioka T, Seto M, Moriyama M. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3ζ. Cancer Res, 2010, 70(6): 2339-2349.[17] Ding L, Xu YJ, Zhang W, Deng YJ, Si MS, Du Y, Yao HM, Liu XY, Ke YH, Si JM, Zhou TH. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res, 2010, 20(7): 784-793.[18] Wada R, Akiyama Y, Hashimoto Y, Fukamachi H, Yuasa Y. miR-212 is downregulated and suppresses methyl-CpG-binding protein MeCP2 in human gastric cancer. Int J Cancer, 2010, 127(5): 1106-1114.[19] Suzuki H, Yamamoto E, Nojima M, Kai M, Yamano HO, Yoshi-kawa K, Kimura T, Kudo T, Harada E, Sugai T, Takamaru H, Ni-inuma T, Maruyama R, Yamamoto H, Tokino T, Imai K, Toyota M, Shinomura Y. Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis, 2010, 31(12): 2066-2073.[20] Bandres E, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X, Zarate R, Diaz-Gonzalez JA, Ramirez N, Sola JJ, Jimenez P, Rodriguez J, Garcia-Foncillas J. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res, 2009, 15(7): 2281-2290.[21] Zhu H, Wu H, Liu XP, Evans BR, Medina DJ, Liu CG, Yang JM. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol, 2008, 76(5): 582-588.[22] Tchernitsa O, Kasajima A, Schäfer R, Kuban RJ, Ungethüm U, Györffy B, Neumann U, Simon E, Weichert W, Ebert MP, Röcken C. Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression. J Pathol, 2010, 222(3): 310-319.[23] Bhatti I, Lee A, Lund J, Larvin M. Small RNA: a large contributor to carcinogenesis? J Gastrointest Surg, 2009, 13(7): 1379-1388.[24] Hummel R, Hussey DJ, Hairer J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer, 2010, 46(2): 298-311.[25] Chellappan P, Xia J, Zhou XF, Gao S, Zhang XM, Coutino G, Vazquez F, Zhang WX, Jin HL. siRNAs from miRNA sites mediate DNA methylation of target genes. Nucleic Acids Res, 2010, 38(20): 6883-6894.[26] Anders M, Vieth M, Röcken C, Ebert M, Pross M, Gretschel S, Schlrag PM, Wiedenmann B, Kemmner W, Höcker M. Loss of the coxsackie and adenovirus receptor contributes to gastric cancer progression. Br J Cancer, 2009, 100(2): 352-359.[27] Ryu HS, Park YL, Park SJ, Lee JH, Cho SB, Lee WS, Chung IJ, Kim KK, Lee KH, Kweon SS, Joo YE. KITENIN is associated with tumor progression in human gastric cancer. Anticancer Res, 2010, 30(9): 3479-3486.[28] Jung Y, Park J, Kim TY, Park JH, Jong HS, Im SA, Robertson KD, Bang YJ, Kim TY. Potential advantages of DNA methyl-transferase 1 (DNMT1)-targeted inhibition for cancer therapy. J Mol Med, 2007, 85(10): 1137-1148.[29] Kim HJ, Jang SH, Jeong YA, Ryu PD, Kim DY, Lee SY. In-volvement of Kv4.1 K(+) channels in gastric cancer cell proliferation. Biol Pharm Bull, 2010, 33(10): 1754-1757.[30] Jeon TY, Han ME, Lee YW, Lee YS, Kim GH, Song GA, Hur GY, Kim JY, Kim HJ, Yoon S, Baek SY, Kim BS, Kim JB, Oh SO. Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer, 2010, 102(4): 710-718.[31] Jeong JY, Woo JH, Kim YS, Choi S, Lee SO, Kil SR, Kim CW, Lee BL, Kim WH, Nam BH, Chang MS. Nuclear factor-kappa B inhibition reduces markedly cell proliferation in Epstein-Barr virus-infected stomach cancer, but affects variably in Epstein-Barr virus-negative stomach cancer. Cancer Invest, 2010, 28(2): 113-119.[32] Choi JH, Song YS, Yoon JS, Song KW, Lee YY. Enhancer of zeste homolog 2 expression is associated with tumor cell prolif-eration and metastasis in gastric cancer. APMIS, 2010, 118(3): 196-202. |
